See more : VK Company Limited (MAIL.IL) Income Statement Analysis – Financial Results
Complete financial analysis of Radius Health, Inc. (RDUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Radius Health, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Greenply Industries Limited (GREENPLY.BO) Income Statement Analysis – Financial Results
- LithiumBank Resources Corp. (LBNKF) Income Statement Analysis – Financial Results
- Maruhachi Securities Co., Ltd. (8700.T) Income Statement Analysis – Financial Results
- Jiangyin Electrical Alloy Co.,Ltd (300697.SZ) Income Statement Analysis – Financial Results
- Blackstone Minerals Limited (BLSTF) Income Statement Analysis – Financial Results
Radius Health, Inc. (RDUS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://radiuspharm.com
About Radius Health, Inc.
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.88B | 3.49B | 2.76B | 1.71B | 173.32M | 99.24M | 22.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.57B | 3.00B | 2.31B | 1.50B | 16.09M | 8.43M | 1.33M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 307.71M | 488.07M | 453.19M | 208.62M | 157.23M | 90.81M | 20.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 10.68% | 14.00% | 16.43% | 12.18% | 90.72% | 91.51% | 93.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 134.63M | 159.71M | 116.76M | 99.91M | 83.08M | 107.41M | 68.28M | 45.72M | 60.54M | 54.96M | 36.18M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 144.15M | 152.70M | 184.16M | 186.68M | 77.54M | 30.80M | 13.67M | 6.83M | 9.47M | 5.33M | 46.78K | 31.99K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 43.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 265.93M | 263.26M | 242.46M | 187.88M | 152.70M | 184.16M | 186.68M | 77.54M | 30.80M | 13.67M | 6.83M | 9.47M | 5.33M | 46.78K | 31.99K | 0.00 |
| Other Expenses | -5.56M | -692.00K | -455.00K | -124.00K | 0.00 | 10.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 265.93M | 263.26M | 242.46M | 187.88M | 269.46M | 294.88M | 269.75M | 184.95M | 99.08M | 59.39M | 67.37M | 64.43M | 41.51M | 46.78K | 31.99K | 0.00 |
| Cost & Expenses | 2.84B | 3.26B | 2.55B | 1.69B | 285.55M | 303.30M | 271.09M | 184.95M | 99.08M | 59.39M | 67.37M | 64.43M | 41.51M | 46.78K | 31.99K | 0.00 |
| Interest Income | 0.00 | 0.00 | 75.00K | 1.40M | 3.93M | 5.62M | 3.23M | 2.44M | 1.04M | 94.00K | 30.00K | 64.00K | 27.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 18.59M | 8.54M | 5.29M | 8.67M | 24.36M | 22.45M | 8.30M | 0.00 | 1.89M | 2.47M | 2.44M | 2.67M | 758.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 89.76M | 75.05M | 58.60M | 58.17M | 2.31M | 2.87M | 1.95M | 586.00K | 176.00K | 77.00K | 27.00K | 44.00K | 40.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | 38.31M | 226.86M | 214.28M | 21.45M | -106.32M | -196.02M | -243.99M | -182.22M | -99.47M | -59.94M | -58.22M | -66.42M | -41.68M | -46.78K | -31.99K | 0.00 |
| EBITDA Ratio | 1.33% | 6.51% | 7.77% | 1.25% | -61.35% | -197.52% | -1,103.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -3.93M | 225.91M | 213.73M | 6.85M | -112.23M | -204.06M | -248.97M | -184.95M | -99.08M | -59.39M | -67.37M | -64.43M | -41.51M | -46.78K | -31.99K | 0.00 |
| Operating Income Ratio | -0.14% | 6.48% | 7.75% | 0.40% | -64.75% | -205.63% | -1,125.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -51.27M | 401.00K | 2.54M | -14.01M | -20.76M | -17.27M | -5.26M | 2.14M | -2.45M | -3.09M | 6.68M | -4.70M | -236.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -28.08M | 216.68M | 207.99M | -1.94M | -132.99M | -221.34M | -254.24M | -182.80M | -101.53M | -62.48M | -60.69M | -69.13M | -14.63M | -46.78K | 0.00 | 0.00 |
| Income Before Tax Ratio | -0.97% | 6.22% | 7.54% | -0.11% | -76.73% | -223.03% | -1,149.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.75M | 44.60M | 37.94M | 166.00K | 3.60M | 5.18M | 3.03M | 2.14M | -564.00K | -619.00K | 9.12M | -2.03M | 522.00K | 0.00 | 31.99K | 0.00 |
| Net Income | -25.79M | 168.80M | 165.11M | -4.15M | -132.99M | -221.34M | -254.24M | -182.80M | -101.53M | -62.48M | -60.69M | -69.13M | -42.48M | -46.78K | -31.99K | 0.00 |
| Net Income Ratio | -0.89% | 4.84% | 5.99% | -0.24% | -76.73% | -223.03% | -1,149.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.92 | 6.01 | 5.90 | -0.15 | -2.89 | -4.88 | -5.80 | -4.24 | -2.56 | -3.53 | -7.94 | -7.11 | -169.92 | -0.02 | -0.01 | 0.00 |
| EPS Diluted | -0.92 | 5.72 | 5.66 | -0.15 | -2.89 | -4.88 | -5.80 | -4.24 | -2.56 | -3.53 | -7.94 | -7.11 | -24.59 | -0.02 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 28.01M | 28.08M | 27.98M | 27.67M | 46.03M | 45.36M | 43.80M | 43.07M | 39.64M | 17.70M | 7.64M | 9.72M | 249.97K | 2.50M | 2.50M | 2.50M |
| Weighted Avg Shares Out (Dil) | 28.01M | 29.53M | 29.19M | 27.67M | 46.03M | 45.36M | 43.80M | 43.07M | 39.64M | 17.70M | 7.64M | 9.72M | 1.73M | 2.50M | 2.50M | 2.50M |
New Strong Sell Stocks for January 26th
Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS
Radius Health Reveals Detailed Elacestrant Data From Late-Stage Breast Cancer Trial
Radius Health to Host Conference Call Today, Wednesday, December 8, 2021
Radius (RDUS) Q3 Loss Wider Than Expected, Stock Declines
Radius Pharmaceuticals, Inc. (RDUS) CEO Kelly Martin on Q3 2021 Results - Earnings Call Transcript
Radius Health (RDUS) Reports Q3 Loss, Misses Revenue Estimates
Earnings Outlook For Radius Health
CORRECTING and REPLACING -- Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021
Radius Health to Announce Third Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Monday, November 8, 2021
Source: https://incomestatements.info
Category: Stock Reports